Foot-and-mouth Variant Hits Iraq Buffaloes

The foot-and-mouth disease has plagued Iraq for decades, but veterinarians call this year's outbreak unprecedented. AFP
The foot-and-mouth disease has plagued Iraq for decades, but veterinarians call this year's outbreak unprecedented. AFP
TT

Foot-and-mouth Variant Hits Iraq Buffaloes

The foot-and-mouth disease has plagued Iraq for decades, but veterinarians call this year's outbreak unprecedented. AFP
The foot-and-mouth disease has plagued Iraq for decades, but veterinarians call this year's outbreak unprecedented. AFP

Despite vaccinating his entire herd against foot-and-mouth disease, Iraqi farmer Saadoun Roumi has lost five of his 15 buffaloes to a variant never before seen in the country.

The severe, highly contagious livestock disease has plagued Iraq for decades, but this year's outbreak has already had a devastating impact described as unprecedented by veterinarians in Nineveh province.

Laboratory tests have identified the SAT2 variant of the viral disease, AFP quoted the United Nations' Food and Agriculture Organization (FAO) as saying.

This strain -- never before recorded in Iraq -- is resistant to the vaccines normally used in the country, leaving authorities scrambling to obtain the right doses to inoculate livestock and prevent further spread.

"The infections are much higher," lamented 26-year-old Roumi from his farm in the village of Badush near Mosul, the capital of Nineveh. "Every day, there are between 20 and 25 cases in the village."

In his yard, he tends to one of his ailing animals, chewing on some fodder in a basin. Along with the five he has already lost, all his buffaloes were vaccinated against the disease as part of a campaign by authorities in 2021.

"The administered vaccines aren't effective," Roumi said. "Foot-and-mouth disease has ravaged the herd."

Between the outbreak and the exorbitant prices of fodder, Roumi like other farmers has seen his only source of livelihood pushed to the brink.

"Before, I used to produce a barrel of 50 kilograms (110 pounds) of milk per day -- now, it's less than 25 kilograms."

Though the disease does not pose a threat to humans, it is highly contagious among "cattle, buffaloes, sheep, goats, swine and other cloven-hoofed", according to FAO.

The disease causes potentially lethal fevers and blisters resulting in "high mortality in newborn and young animals, weight loss, reduced milk yields and lower fertility", the UN agency said.

"Affected animals become too weak to be used to plough the soil or reap harvests, and farmers cannot sell the milk they produce, which can severely impact household food security."

Udai al-Abadi, the director of a veterinary hospital in Nineveh, noted that the disease "resurges in intermittent waves", with the last peak in 1998.

But this year, "infections are high and can be counted in the hundreds" in the province, compared with the dozens usually recorded, he said.

"More than a hundred cattle have died."

Urgent requests for vaccines have been sent to the government in Baghdad, he said, but the province did not receive its allocation of shots in 2022, though they can be purchased locally from private sellers.

Saadoun Roumi's 90-year-old father Balou said he lost a calf from his herd of 20 buffaloes.

"When foot-and-mouth disease hits the animal, its milk is unusable and its legs can barely carry it," he said.

Khalid Shlash, assistant to the FAO representative in Iraq, explained that analysis of 12 samples in Nineveh, Baghdad and Diyala provinces identified the responsible strain -- SAT2, which stands for "Southern African Territories" where it originated.

He said the strain was not previously present in Iraq and therefore the corresponding vaccine had never been used there.

In a bid to curb the outbreak, authorities have launched disinfection campaigns and imposed restrictions on the movement of livestock, Shlash said.

He noted that the FAO is offering its expertise to support the government's efforts, noting that the priority now is for a specialized lab to identify the right vaccine.

Baghdad must then find a producer to supply nine million doses of the vaccine, he added.

"From where and how did this virus come to Iraq?" he said. "This is the question veterinarian services are now trying to answer."



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”